Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
Key Highlights
- ➤KRRO-111 achieved 96% SERPINA1 mRNA editing in repeat-dose NSG-PiZ mice
- ➤Total AAT reached 172 μM, approximately sixfold above vehicle at Day 57
- ➤KRRO-111 reduced whole-liver Z-AAT levels 95% versus vehicle control
- ➤Regulatory submission for KRRO-111 expected in the first half of 2027
Expert Statements
Loïc Vincent, Chief Scientific Officer of Korro
“In these preclinical studies, KRRO-111 restored functional M-AAT while reducing the toxic Z-AAT that drives liver injury.”
Loïc Vincent, Chief Scientific Officer of Korro
“That dual profile, with a redosable subcutaneous drug presentation, is what we believe a next-generation AATD therapy needs to support all AATD patients.”
Ram Aiyar, Chief Executive Officer and President of Korro
“People living with AATD face both lung and liver disease. Augmentation therapy addresses only part of that burden while there is no approved therapy for the liver disease.”
Ram Aiyar, Chief Executive Officer and President of Korro
“Based on the strength and consistency of these data, we believe KRRO-111 has the potential to become a transformative therapy for both the lung and liver manifestations of AATD, and we look forward to advancing it into the clinic in the first half of 2027.”
* Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold * KRRO-111 reduced pathogenic hepatic Z-AAT by up to 95%, highlighting its potential to reduce toxic protein accumulation in the liver * Best-in-class preclinical profile supports KRRO-111’s potential to address both liver and lung manifestations of AATD; regulatory submission expected in the first half of 2027 CAMBRIDGE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its novel oligonucleotide promoted editing of RNA (OPERA(®)) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced preclinical results for its pipeline program KRRO-111 for the potential treatment of alpha-1 antitrypsin deficiency (AATD) delivered subcutaneously. The results highlight KRRO-111’s potential best-in-class profile and its ability to address both the lung and liver manifestations of AATD through a differentiated RNA editing approach.
Get started
Create a free account to read the full story.